Sequencer Products: SEQ ALL
Technologies
Applications
Online Resources
Data Bulletins
Service & Support
Introduction
Newsroom
Doing Business With Us
Creative Club
As the application field of MGI's Platform based on DNBSEQ ™ technology becomes more diverse and broader, MGI Platform integrates many excellent companies in the industry with their natural principle advantages, open and shared compatibility, and continuous innovation of technology products, aiming to jointly build an open industry ecology.
Recently, MGI and a number of institutions in the Asia-Pacific region reached a cooperation intention to jointly build a high-throughput sequencing platform. In order to further expand the type of adaptive applications, it will together with Beijing Genetron Technology Co., Ltd. (hereinafter referred to as " Genetron") to use the patented technology of "One Step" of on the DNBSEQ platform. At present, it has achieved a lower sample starting volume and faster and stable data output. Through this cooperation, MGI has enabled innovative technology to empower the upstream and downstream of the industrial chain and jointly expand overseas business.
MGI's DNBSEQ ™ sequencing technology has high accuracy, low repetition rate, and low index hopping. The upgraded CoolMPS high-throughput sequencing reagent kit has higher accuracy and can be better applied to tumor low-frequency detection applications.
Genetron's unique "one-step" method of building a database can replace the existing tedious process of building a database, condensing multiple steps to the extreme, and turning it into a "one-step" chemical reaction in a tube. From the time, the traditional library construction time of 1-2 days was shortened to only 1.5 hours, including manual operation of only 5 minutes. At present, the tumor susceptibility gene BRCA1 / 2 full exon detection kit developed based on the "one-step method", human tumor drug guidance gene detection. The kit has completed thousands of sample verifications. Combined with MGISP-100 automated equipment, it can make high-throughput sequencing experiments lower the risk of cross-contamination, less manual operations, more stable data output, and truly promote gene sequencing. And it helps the development of precision medicine.
